Perspective Therapeutics' pipeline, led by VMT-a-NET, shows promising safety and early efficacy, but lacks clear superiority over existing therapies like Lutathera so far. The company maintains a ...
Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to ...
LONDON, UK, 4 March 2025 - In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumours (NETs), a ...
Radiation Research, Vol. 152, No. 6, Supplement: The International Workshop on the Health Effects of Thorotrast, Radium, Radon and Other Alpha-Emitters 1999 (Dec., 1999), pp. S43-S47 (5 pages) There ...
OSLO, Norway, June 6, 2023 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") and Thor Medical AS ("Thor Medical"), a privately held company focused on the ...
"A series of studies carried out at the University of Rochester School of Medicine and Dentistry, Dept. of Radiation Biology, Atomic Energy Project." siris_sil_94710 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback